Ra Capital Management, L.p. bought $25k of CLYM
director, owner at Eliem Therapeutics, Inc.. 7,111 shares at an average of $3.50, traded Jan 5, 2026, filed Jan 7, 2026.
Score components
- +15RoleDirector
- 0Trade size$25k at market
- -5Relative to holdingsUnder 1% of holdings (0.2%)
- +4Price context28% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- -5Track recordMedian 6-month excess return -38% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +29.5%, 3m +69.0%, 6m +223.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000018, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +7,111 | $3.50 | $25k | 3,403,429 | Jan 7, 2026 |
Related signals
Other insiders at Eliem Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $1.4M 100,000 shares | -18% | |
| 16Weak | Eliem Therapeutics, Inc. | Aoife Brennan President and CEO | $407k 30,902 shares | -26% | |
| 15Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $350k 50,000 shares | -24% | |
| 23Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $529k 100,000 shares | -33% | |
| 39Weak | CLYMbuy Eliem Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $755k 314,561 shares | +10% | |
| 13Weak | Eliem Therapeutics, Inc. | Aoife Brennan President and CEO | $25k 20,618 shares | -30% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,540 1,242 shares | -6% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,571 1,199 shares | -7% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $2,495 1,235 shares | -10% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $9,741 1,191 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.